Should You Buy Cellebrite DI Ltd (CLBT) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
16.010
1 Day change
-3.50%
52 Week Range
26.300
Analysis Updated At
2026/01/28
BUY (starter position now). CLBT is pulling back toward support (~15.79) with improving bullish options sentiment (puts relatively low vs calls) and a clearly positive analyst trend (targets raised to ~$23–$25). For a beginner long-term investor who doesn’t want to wait for a perfect entry, the current dip offers a reasonable entry ahead of the Feb-11 earnings catalyst, despite near-term technical weakness and earnings-related risk.
Technical Analysis
Price/Trend: CLBT is weakening short-term (today -2.11% to 16.255) and trading below the pivot (16.749), which keeps near-term momentum cautious.
Momentum: MACD histogram is negative (-0.129) but “negatively contracting,” suggesting downside momentum may be fading rather than accelerating.
RSI: RSI(6)=39.26—below midline and closer to oversold than overbought, consistent with a pullback rather than a euphoric top.
Moving averages: Converging MAs indicates consolidation/transition; not a strong uptrend signal yet.
Key levels: Support S1=15.788 (near-term buy zone/defense area). If that breaks, next support S2=15.195. Overhead resistance: Pivot 16.749 then R1=17.71.
Bottom line: Technically this looks like a dip/consolidation near support (not a breakout), which can still be a fine long-term entry if you accept short-term noise.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Put/Call ratios are low (OI PCR 0.35; Volume PCR 0.42), indicating call-heavy positioning and generally bullish sentiment.
Volatility: 30D IV ~55.38 vs historical vol ~70.2; IV percentile ~65.2 (options relatively expensive vs much of the past year). This often coincides with an upcoming catalyst (earnings) and heightened positioning.
Activity: Today’s option volume is light vs 5D/10D averages, but open interest is call-dominant (calls 16,823 vs puts 5,901), reinforcing the bullish skew.
Interpretation: Options positioning is supportive (bullish skew) into the next event window.
Technical Summary
Sell
10
Buy
1
Positive Catalysts
Business traction narrative: Technology used by 7,000+ agencies and supports large-scale investigations—supports a durable demand story for long-term holders.
Neutral/Negative Catalysts
Earnings risk (near-term): With earnings approaching, any miss or cautious 2026 guidance can pressure the stock.
Profitability volatility: Latest quarter showed sharp YoY declines in Net Income and EPS (even as revenue grew), which can weigh on confidence if it persists.
Technical overhang: Stock is below the pivot and MACD remains negative—short-term traders may sell rallies until a clearer uptrend returns.
High-ish implied volatility: IV percentile ~65 can amplify price swings around events.
Financial Performance
Latest reported quarter: 2025/Q3.
Growth: Revenue rose to $126.029M, +17.94% YoY—solid top-line growth.
Profitability: Net income fell to $20.189M (-109.75% YoY) and EPS declined to $0.08 (-108.08% YoY), indicating significant YoY compression (potentially mix/expenses/one-time effects in the prior year).
Margins: Gross margin remained very high at 83.88%, down modestly (-1.95% YoY), suggesting the core business still has strong unit economics.
Takeaway: Strong revenue growth and high gross margins support a long-term thesis, but recent earnings volatility is the key item to monitor into the Feb-11 release.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Clearly improving. On 2025-11-13, JPMorgan raised PT to $24 (Overweight), BofA raised PT to $25 (Buy), and Lake Street raised PT to $23 (Buy) after Q3.
Wall Street pro view (pros): Growth levers into 2026, improving underlying trends, and confidence the business is “back on track.”
Wall Street con view (cons): Prior “two consecutive quarters of disappointment” were noted; investors will likely demand continued execution and steadier profitability.
Influential/Politician trading: No recent congress trading data available; hedge fund and insider trend signals are neutral.
Intellectia Proprietary Trading Signals: No signal on given stock today.
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.2 USD with a low forecast of 23 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.2 USD with a low forecast of 23 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
1 Sell
Moderate Buy
Current: 16.590
Low
23
Averages
24.2
High
25
Current: 16.590
Low
23
Averages
24.2
High
25
JPMorgan
Brian Essex
Overweight
maintain
$23 -> $24
AI Analysis
2025-11-13
Reason
JPMorgan
Brian Essex
Price Target
$23 -> $24
AI Analysis
2025-11-13
maintain
Overweight
Reason
JPMorgan analyst Brian Essex raised the firm's price target on Cellebrite to $24 from $23 and keeps an Overweight rating on the shares. The company reported solid Q3 results with "multiple levers" to drive growth in 2026, the analyst tells investors in a research note.
BofA
Buy
maintain
$24 -> $25
2025-11-13
Reason
BofA
Price Target
$24 -> $25
2025-11-13
maintain
Buy
Reason
BofA raised the firm's price target on Cellebrite to $25 from $24 and keeps a Buy rating on the shares. The firm fine tunes its estimates to reflect positive underlying trends following the company's Q3 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLBT
